TAIPEI, Taiwan, May 22, 2019 /PRNewswire/ -- The possible
correlation between autism spectrum disorder (ASD) and gut
microbiota has long been explored. A recent study, published
in《Nutrients》, shows that a
specific probiotic supplementation composed of Lactobacillus
plantarum PS128 (Psychobiotic PS128™,
commercialized by Bened Biomedical Co., Ltd.) may
significantly alleviate symptoms of Autism spectrum disorder (ASD)
and Attention Deficit Hyperactivity Disorder (ADHD).
The study titled "Effects of Lactobacillus plantarum
PS128 on Children with Autism
Spectrum Disorder in Taiwan: A
Randomized, Double-Blind, Placebo-Controlled Trial" was conducted
by Prof. Ying-Chieh Tsai of National
Yang-Ming University and the ASD experts in Taiwan. It is the first study utilizing
probiotics over a double-blind, randomized, parallel-group,
placebo-controlled clinical trial for behavioral improvement in
subjects with ASD, which sets a
milestone in research on the relationship between autism and
probiotics.
In this 4-week intervention study, a total of 80 boys with ASD
aged 7-15 were included and randomized to receive either PS128 (30
billion CFU/capsule) or placebo with daily doses of 2 capsules. The
results showed that PS128 significantly ameliorated opposition and
defiance behaviors. In addition,
the total score of the questionnaires for
ADHD and oppositional defiant disorder, SNAP-IV, for younger
children (aged 7-12) improved significantly compared with the
placebo group.
Autism spectrum disorder (ASD) is a developmental disorder that
affects communication and social behaviors. According to the
WHO, it is estimated that 1 in 160 children worldwide suffer from
ASD, with the US more than doubling that ratio at 1 in 59 children
instead. While ASD has been so prevalent, there have been no
effective cures to date; early intervention has been the main
treatment for children with developmental disorders. Recent animal
studies have also found that specific probiotic strain can regulate
brain hormones and improve symptoms of autism.
According to Prof. Ying-Chieh
Tsai, two further clinical studies investigating the effects
of Psychobiotic PS128™ on children with ASD are also underway. In
Taiwan, "Psychophysiological
effects of Lactobacillus plantarum PS128 in preschool
children with autism spectrum disorder: a randomized,
placebo-controlled trial" including preschool children with ASD was
conducted in a teaching hospital in Taipei. And "The effects of probiotics and
oxytocin nasal spray on social behaviors of ASD children- a pilot
study" was an international collaborative study with the
Massachusetts General Hospital.
Besides the successful ASD and ADHD studies, there have been
several other clinical studies underway for PS128 targeting
Central Nervous System (CNS)
disorders such as Parkinson's disease, depression, anxiety,
Tourette syndrome, etc.
Reference: "Effects
of Lactobacillus plantarum PS128 on Children with Autism Spectrum
Disorder in Taiwan: A Randomized, Double-Blind, Placebo-Controlled
Trial." Nutrients, 2019 Apr 11;11(4),
https://www.ncbi.nlm.nih.gov/pubmed/30979038
|
ABOUT Psychobiotic PS128™
Psychobiotic PS128™, the winner of "Probiotic Product of the
Year" for the 2018 NutraIngredients-Asia Awards, is a novel
psychobiotic that can modulate microbiota-gut-brain axis. As
proven in the lab research and scientific publications, daily
consumption of PS128™ can increase the concentration of
dopamine and serotonin in key brain areas such as the prefrontal cortex or hippocampus. PS128™ is
proven effective in preventing, alleviating and treating mental and
movement disorders including autism, depression, anxiety, insomnia,
IBS, Parkinson's disease, etc. The first PS128™ product was
commercialized in 2015 by Bened Biomedical Co., Ltd. and is now
available as a dietary supplement in more than 15 countries in the
world.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bened-biomedical-co-ltd-psychobiotic-ps128tm-found-to-be-a-potential-solution-for-autism-spectrum-disorder-asd-and-attention-deficit-hyperactivity-disorder-adhd-300855678.html
SOURCE Bened Biomedical Co., Ltd.